Share

May 23, 2017; 88 (21) Article

Hypothalamus as a mediator of chronic migraine

Evidence from high-resolution fMRI

Laura H. Schulte, Angie Allers, Arne May
First published April 26, 2017, DOI: https://doi.org/10.1212/WNL.0000000000003963
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
376

Share

Article Information

vol. 88 no. 21 2011-2016
DOI: 
https://doi.org/10.1212/WNL.0000000000003963
PubMed: 
28446645
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received November 30, 2016
  • Accepted in final form March 1, 2017
  • First Published April 26, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. Laura H. Schulte, MD,
    2. Angie Allers, MD and
    3. Arne May, MD, PHD
  1. Laura H. Schulte, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Allergan: travel funding for conference attendance

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. University Medical Center Hamburg Eppendorf (2011 to present)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Angie Allers, MD and
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Arne May, MD, PHD
    4. Scientific Advisory Boards:

    1. advisory boards: ATI, (2014-2015); Desitin (2014-2015), Allergan(2014-2015)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria in the last 2 years (only 2015, none in 2016): Pfizer, Allergan, TEVA

    Editorial Boards:

    1. Cephalalgia (editor-in-chief)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. SFB 936 ?Multi-Site Communication in the Brain?, project A5 Deutsche Forschungsgemeinschaft (DFG) (MA 1862/2-3)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Systems Neuroscience, University Medical Center Eppendorf, Hamburg, Germany.
  1. Correspondence to Dr. May: a.may{at}uke.de
View Full Text

Article usage

Article usage: April 2017 to June 2019

AbstractFullPdfSource
Apr 2017648017Highwire
May 2017311230100Highwire
Jun 20177081935Highwire
Jul 2017277918Highwire
Aug 2017190615Highwire
Sep 2017183916Highwire
Oct 201710269Highwire
Nov 201710669Highwire
Dec 201785119Highwire
Jan 2018841117Highwire
Feb 201894118Highwire
Mar 2018861711Highwire
Apr 20189689Highwire
May 2018108911Highwire
Jun 20185328Highwire
Jul 20185155Highwire
Aug 20184513Highwire
Sep 201896614Highwire
Oct 2018105712Highwire
Nov 20181071312Highwire
Dec 20185411Highwire
Jan 201910346Highwire
Feb 20196447Highwire
Mar 20195979Highwire
Apr 20198947Highwire
May 201910755Highwire
Jun 20196113Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me